|Bid||15.05 x 800|
|Ask||38.88 x 800|
|Day's Range||21.72 - 22.21|
|52 Week Range||20.83 - 39.89|
|Beta (3Y Monthly)||1.51|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||37.75|
LONDON, Jan. 07, 2019 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 37th.
– Global SAVANNAH study of savolitinib / Tagrisso® combination in MET+ EGFRm NSCLC underway. Data presented at ESMO 2018 showed MET-amplification among themost frequent.
– Chi-Med acquires right to determine & conduct all future life cycle indication development of fruquintinib monotherapy as well as innovative combinations in China – –.
Nov 29 (Reuters) - Innovent Biologics Inc: * HAS ENTERED INTO A GLOBAL COLLABORATION AGREEMENT WITH HUTCHISON CHINA MEDITECH LIMITED * UNDER AGREEMENT, UNIT INNOVENT SUZHOU AND HUTCHISON MEDIPHARMA TO ...
LONDON, Nov. 29, 2018 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) entered into four collaboration agreements to evaluate the safety, tolerability and.
LONDON, Nov. 26, 2018 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces the first commercial launch of fruquintinib capsules (Elunate®) with the.
– Trial did not meet the primary endpoint of overall survival despite improvement in progression-free survival – LONDON, Nov. 16, 2018 -- Hutchison China MediTech Limited.
Hutchison China MediTech has won Chinese approval for a closely watched new cancer drug in a significant boost for "made in China" medicine. The London-listed company - which is known as Chi-Med and is collaborating with Eli Lilly on the drug - said on Wednesday that the National Medical Products Administration of China had approved Elunate or fruquintinib in colorectal cancer. It is one of the first modern medicines discovered and developed in China, and the speedy green light from Chinese authorities is further evidence of the country's progress in speeding up drug approvals.
Hutchison China Meditech CEO Christian Hogg discusses the importance of capitalizing on opportunities and shares his outlook for biotech. (Source: Bloomberg)
NEW YORK, NY / ACCESSWIRE / July 27, 2018 / Hutchison China MediTech Limited Sponsored ADR (NASDAQ: HCM ) will be discussing their earnings results in their H1 Earnings Call to be held on July 27, 2018 ...
Does the share price for Hutchison China MediTech Limited (AIM:HCM) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value using the discounted cash flow (DCF) method. IfRead More...
NEW YORK , March 16, 2018 /PRNewswire/ -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on March 21 st and 22 nd , featuring live ...
Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Hutchison China MediTech Limited (NASDAQ:HCM), with a market cap of US$4.50B, are often out ofRead More...
Hutchison China MediTech Limited has initiated a Phase Ib/II proof-of-concept study of epitinib in glioblastoma patients with epidermal growth factor receptor gene amplification in China.
Investors tend to look for stocks that have a strong future outlook. Why invest in something that will grow slower than the rest of the market? In terms of profitabilityRead More...
Hutchison China MediTech Limited has completed patient enrollment of FALUCA, its Phase III pivotal trial of fruquintinib in advanced, third-line, non-small cell lung cancer patients in China.